Rational Approaches to the Design of Therapeutics Targeting Molecular Markers: The Case of Chronic Myelogenous Leukemia

@article{Saglio2004RationalAT,
  title={Rational Approaches to the Design of Therapeutics Targeting Molecular Markers: The Case of Chronic Myelogenous Leukemia},
  author={Giuseppe Saglio and Alessandro Morotti and Giovanna Mattioli and Emanuela Messa and Emilia Giugliano and Gisella Volpe and Giovanna Rege‐Cambrin and Daniela Cilloni},
  journal={Annals of the New York Academy of Sciences},
  year={2004},
  volume={1028}
}
Abstract: Progress in understanding the molecular basis of signal transmission and transduction has contributed substantially to clarifying the mechanisms of leukemogenesis and of leukemia progression and has led to the identification of a number of specific molecular targets for treatment. Chronic myeloid leukemia (CML) has provided one of the best models, as the identification of a leukemia‐specific hybrid tyrosine kinase (BCR‐ABL, p210, p190) has led to the identification and the successful… 
Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells
TLDR
New insights into the mechanisms of resistance to TKIs are summarized and it remains clear that tyrosine kinase inhibitors are unable to target the most immature cellular component of CML, the CML stem cell.
Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias
TLDR
The role of BCR-ABL/protein kinase CK2 interaction in BCR -ABL leukemias is reviewed, with potentially relevant implications for therapy.
The BCR-ABL/NF-κB signal transduction network: a long lasting relationship in Philadelphia positive Leukemias
TLDR
The role of NF-κB in BCR-ABL-mediated leukemogenesis is summarized and new insights are provided on the long lasting BCR -ABL/NF-κBs connection.
BLCTT_A_228815 45..52
TLDR
A review summarizes new insights into the mechanisms of resistance to TKIs and shows that tyrosine kinase inhibitors are unable to target the most immature cellular component of CML, the CML stem cell.
Non genomic loss of function of tumor suppressors in CML: BCR-ABL promotes IκBα mediated p53 nuclear exclusion
TLDR
It is shown that BCR-ABL promotes the accumulation of the NFKBIA gene product, IκBα, in the cytosol through physical interaction and stabilization of the protein, and a novel B CR-AB l/IκB α/p53 network functionally inactivates a key tumor suppressor.
A Case Report of Personalized Chemotherapy for Metastatic Cardiac Sarcoma
TLDR
A personalized chemotherapy to treat a patient suffering from cardiac sarcoma with multiple metastases is reported, successfully select FDA approved drugs to treat the patient and achieve a partial response for the patient.
Cytogenetic investigation in chronic myeloid leukemia: study from an Indian population.
TLDR
Availability of more advanced molecular techniques can be used as a supportive tool in CML diagnosis even though it cannot fully replace cytogenetics, which remains the backbone for laboratory investigation of the disease.
BCR-ABL inactivates cytosolic PTEN through Casein Kinase II mediated tail phosphorylation
TLDR
It is shown that nuclear exclusion of PTEN is associated with PTEN inactivation in the cytoplasm of CML cells, and a novel BCR-ABL/CKII/PTEN pathway is proposed as a potential target to achieve synthetic lethality with tyrosine kinase inhibitors.
Nuclear-cytoplasmic Shuttling in Chronic Myeloid Leukemia: Implications in Leukemia Maintenance and Therapy
TLDR
The role of various shuttling components in Chronic Myeloid Leukemia is recapitulate and insights are provided on the potential role ofshuttling proteins as therapeutic targets.
...
...

References

SHOWING 1-10 OF 45 REFERENCES
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
TLDR
STI571 is well tolerated and has significant antileukemic activity in patients with CML in whom treatment with interferon alfa had failed and demonstrates the potential for the development of anticancer drugs based on the specific molecular abnormality present in a human cancer.
Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.
TLDR
The data support that in CML patients treated with STI571, ABL mutations are not restricted to the accelerated phase of the disease and that, at least in some cases, mutations seem to occur prior to STi571 therapy, probably as second mutational events during the course of CML.
Imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia: current status and evolving concepts.
Until recently, progress in the treatment of patients with Ph(+) acute lymphoblastic leukaemia (ALL) has been limited, and long-term survival, even with high-dose intensified chemotherapy, is rare.
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
TLDR
It is found that drug resistance is associated with the reactivation of BCR-ABL signal transduction in all cases examined and a strategy for identifying inhibitors of STI-571 resistance is suggested.
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
TLDR
Imatinib mesylate induces durable responses in patients with chronic myeloproliferative diseases associated with activation of PDGFRB and all responses were durable at 9 to 12 months of follow-up.
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia.
TLDR
The cytogenetic and molecular response (CgR, MR) to imatinib in 191 patients with late chronic-phase Philadelphia-positive CML, previously treated with interferon alpha is determined, concluding that in CCgRs the degree of MR may vary from 2 to more than 4 logs, and that there is a progressive decrease of transcript level by time.
The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia.
TLDR
It is concluded that heterogeneous alterations in the p53 gene and occasionally in the N-RAS genes accompany the evolution of chronic phase CML to blast crisis.
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
TLDR
Orally administered imatinib is an effective and well-tolerated treatment for patients with CML in accelerated phase, and a daily dose of 600 mg is more effective than 400 mg, with similar toxicity.
Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.
TLDR
It is concluded that BCR-ABL-positive cells can evade the inhibitory effect of STI571 by different mechanisms, such as Bcr-Abl overexpression, reduced intake mediated by Pgp, and, possibly, acquisition of compensatory mutations in genes other than BCR -ABL.
...
...